Blog

Contributors: Julie Gil, Ph.D., Sarah Kleinstein, Ph.D., Cera Fisher, Ph.D., Dennis Dean Ph.D., and Kristina Clemens Ph.D. During the COVID-19 pandemic, many of us gained first-hand experience of the efficacy of mRNA vaccines. Twenty years of dedicated research in the general application of mRNA vaccines fueled the rapid delivery of …

At Velsera, we’re passionate about paving the way for the future of bioinformatics and regulatory excellence. We collaborated with the BioCompute Object (BCO) community to develop the BCO standard for communicating complex Next Generation Sequencing (NGS) workflows for regulatory review and developed an award-winning app that generates BCOs from complex …

Limited by computational resources, the Khiabanian lab at Rutgers needed a breakthrough.   The lab was looking at rare changes in blood cells linked to a condition called CHIP (clonal hematopoiesis of indeterminate potential). This condition has been associated with certain types of treatment-induced cancers as well as resistance to cancer …

The power – and increasing cost-effectiveness – of ‘omic technologies has provided groundbreaking insights into the underpinnings of biology and has revolutionized the process of target and drug discovery.  A method like transcriptomics can provide a snapshot of genetic activity under certain conditions while proteomics can tell us which of …

I have long been fascinated with data’s power to drive new insights, including developing a deeper understanding of human physiology/pathophysiology, informing decision-making, and guiding the development of new treatment options. Often novel complex analysis methods are linked to specialized visualizations to drive the development and use of these insights. My …

In recent years, precision medicine has witnessed remarkable progress, thanks to multi-omics and multi-modal data integration.[1,2] This holds immense potential for advancing healthcare in various domains, such as risk target identification, trial design, diagnostic analytics, population health analysis, lab automation, and clinical decision support[3,4,5]. Whether you are part of industry, …

This month represented an important step forward in the treatment of Alzheimer’s disease with Eli Lilly announcing the successful results of their phase III clinical trials for their monocolonal antibody (mAB) donanemab. In addition to decreasing the overall amyloid burden, patients on the drug showed slowed disease progression and sustained …